{"organizations": [], "uuid": "544f956e031fe2bfbc6d71f1df38e9158944efd9", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180430.html", "section_title": "Archive News &amp; Video for Monday, 30 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-evelo-biosciences-sees-ipo-of-531/brief-evelo-biosciences-sees-ipo-of-5-31-mln-shares-of-its-common-stock-priced-to-be-between-15-17-share-idUSFWN1S70MY", "country": "US", "domain_rank": 408, "title": "BRIEF-Evelo Biosciences Sees IPO Of 5.31 Mln Shares Of Its Common Stock Priced To Be Between $15-$17/ Share", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.062, "site_type": "news", "published": "2018-04-30T19:06:00.000+03:00", "replies_count": 0, "uuid": "544f956e031fe2bfbc6d71f1df38e9158944efd9"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-evelo-biosciences-sees-ipo-of-531/brief-evelo-biosciences-sees-ipo-of-5-31-mln-shares-of-its-common-stock-priced-to-be-between-15-17-share-idUSFWN1S70MY", "ord_in_thread": 0, "title": "BRIEF-Evelo Biosciences Sees IPO Of 5.31 Mln Shares Of Its Common Stock Priced To Be Between $15-$17/ Share", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "evelo biosciences inc", "sentiment": "negative"}, {"name": "sec", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 30 (Reuters) - Evelo Biosciences Inc:\n* EVELO BIOSCIENCES INC SEES IPO OF 5.31 MILLION SHARES OF ITS COMMON STOCK PRICED TO BE BETWEEN $15.00 AND $17.00 PER SHARE - SEC FILING\n* EVELO BIOSCIENCES INC - INTENDS TO USE ABOUT $45-$50 MILLION OF IPO PROCEEDS TO FUND PROOF OF CONCEPT CLINICAL TRIALS IN INFLAMMATORY DISEASES PROGRAMS\n* EVELO BIOSCIENCES INC - INTENDS TO USE ABOUT $25-$35 MILLION OF IPO PROCEEDS TO FUND PROOF OF CONCEPT CLINICAL TRIALS IN ONCOLOGY PROGRAMS\n* EVELO BIOSCIENCES -INTENDS TO USE ABOUT $35-$45 MILLION OF IPO PROCEEDS TO INVEST IN PLATFORM AND TO ADVANCE ADDITIONAL PRECLINICAL DEVELOPMENT ACTIVITIES Source text ( bit.ly/2rbI2ON )\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/", "https://bit.ly/2rbI2ON"], "published": "2018-04-30T19:06:00.000+03:00", "crawled": "2018-05-01T20:13:03.000+03:00", "highlightTitle": ""}